ZYME Stock Recent News

In the pulsating realm of small-cap stocks, a select few emerge as trailblazers, poised to revolutionize industries and redefine investment landscapes. Enter the triumphant trio of three under-the-radar companies orchestrating remarkable healthcare, biotechnology and cryptocurrency mining feats.

The average of price targets set by Wall Street analysts indicates a potential upside of 42.8% in Zymeworks Inc. (ZYME). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

VANCOUVER, British Columbia, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference:

Zymeworks Inc. (NASDAQ:ZYME ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Shrinal Inamdar – Director-Investor Relations Chris Astle – Senior Vice President and Chief Financial Officer Paul Moore – Chief Scientific Officer Ken Galbraith – Chair and Chief Executive Officer Conference Call Participants Jonathan Miller – Evercore Ashiq Mubarack – Citi Charles Zhu – Guggenheim Securities Ivy Wang – Jefferies Stephen Willey – Stifel Brian Cheng – JPMorgan Operator Good day, and thank you for standing by. Welcome to the Zymeworks Third Quarter 2023 Results Conference Call.

VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences:

VANCOUVER, British Columbia, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its third quarter 2023 financial results after market close on November 7, 2023. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on November 7, 2023 at 4:30 p.m. Eastern Time (ET).

Zymeworks is a biotech company focused on developing therapies for hard-to-treat cancers. Its lead product, zanidatamab, has shown promising results in clinical trials and has been partnered with larger pharmaceutical companies. The company also has a pipeline of early-stage candidates and a potential for substantial upside through its partnerships and commercialization of zanidatamab.

Zymeworks Inc. (NASDAQ:ZYME ) Q2 2023 Earnings Call August 10, 2023 4:30 PM ET Company Participants Diana Papove - Director of Corporate Communications Chris Astle - Senior Vice President and Chief Financial Officer Kenneth Galbraith - Chair and Chief Executive Officer Paul Moore - Chief Scientific Officer Conference Call Participants Jon Miller - Evercore Yigal Nochomovitz - Citigroup Charles Zhu - Guggenheim Brian Cheng - JP Morgan Operator Thank you for standing by. This is the conference operator.

Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.97 per share a year ago.

VANCOUVER, British Columbia, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: